Treatment of Gram-positive left-sided infective endocarditis with daptomycin

Kaya, Selçuk; Yılmaz, Gürdal; Kalkan, Ahmet; Ertunç, Barış; Köksal, İftihar

doi:10.1007/s10156-012-0546-9

Cited by 10 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study principally aimed to compare in-hospital mortality rates between patients treated with daptomycin and patients treated with SOC for left-sided IE due to S. aureus, CoNS, and E. faecalis. Secondary objectives of the study included the following: (i) to compare 6-month mortality rates of patients in cohort A and patients in cohort B, (ii) to determine if there was a relationship between dose of daptomycin and time to clearance of bacteremia and/or adverse events in cohort A, and (iii) to assess the incidence of specific adverse events which have been related to the use of daptomycin, including significant elevation of CPK, peripheral neuropathy, and eosinophilic pneumonia (8,9,13,16).…”

Section: Methodsmentioning

confidence: 99%

“…Since that time, the successful use of daptomycin in the treatment of IE due to other Gram-positive organisms, including coagulase-negative staphylococci (CoNS), streptococci, Enterococcus faecalis, and Corynebacterium, has been reported (9)(10)(11)(12)(13). Recent literature suggests that daptomycin may be useful in the treatment of left-sided IE as well as right-sided IE (14)(15)(16). Despite these individual reports, there has not been a prospective comparative evaluation of daptomycin in the treatment of Grampositive IE in well-defined clinical left-sided IE cases.…”

mentioning

confidence: 99%

See 1 more Smart Citation

High-Dose Daptomycin Therapy for Left-Sided Infective Endocarditis: a Prospective Study from the International Collaboration on Endocarditis

Carugati

Bayer

Miró

et al. 2013

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The use of daptomycin in Gram-positive left-sided infective endocarditis (IE) has significantly increased. The purpose of this study was to assess the influence of high-dose daptomycin on the outcome of left-sided IE due to Gram-positive pathogens. This was a prospective cohort study based on 1,112 cases from the International Collaboration on Endocarditis (ICE)-Plus database and the ICE-Daptomycin Substudy database from 2008 to 2010. Among patients with left-sided IE due to Staphylococcus aureus, coagulase-negative staphylococci, and Enterococcus faecalis, we compared those treated with daptomycin (cohort A) to those treated with standard-of-care (SOC) antibiotics (cohort B). The primary outcome was in-hospital mortality. Time to clearance of bacteremia, 6-month mortality, and adverse events (AEs) ascribable to daptomycin were also assessed. There were 29 and 149 patients included in cohort A and cohort B, respectively. Baseline comorbidities did not differ between the two cohorts, except for a significantly higher prevalence of diabetes and previous episodes of IE among patients treated with daptomycin. The median daptomycin dose was 9.2 mg/kg of body weight/day. Two-thirds of the patients treated with daptomycin had failed a previous antibiotic regimen. In-hospital and 6-month mortalities were similar in the two cohorts. In cohort A, median time to clearance of methicillin-resistant S. aureus (MRSA) bacteremia was 1.0 day, irrespective of daptomycin dose, representing a significantly faster bacteremia clearance compared to SOC (1.0 versus 5.0 days; P < 0.01). Regimens with higher daptomycin doses were not associated with increased incidence of AEs. In conclusion, higher-dose daptomycin may be an effective and safe alternative to SOC in the treatment of left-sided IE due to common Gram-positive pathogens.

show abstract

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

High-Dose Daptomycin Therapy for Left-Sided Infective Endocarditis: a Prospective Study from the International Collaboration on Endocarditis

Carugati

Bayer

Miró

et al. 2013

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Underlying heart diseases in percentage (from references number:[6,15,19,20,[25][26][27][28][29][30][31][32][33][35][36][37]39,40],). Involved infection sites in cases (from references number:[6,15,19,20,[25][26][27]30,31,[33][34][35][36]39,40]). …”

mentioning

confidence: 99%

Pooled analysis of 1270 infective endocarditis cases in Turkey

Vahabi

Gül

Garakhanova

et al. 2019

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Despite developments in medicine, infective endocarditis (IE) is still associated with significant morbidity and mortality. In this study it was aimed to systematically review the infective endocarditis literature published or presented from Turkey. Methods: To find the published series, one national database (Ulakbim), and three international databases (Scopus, Pubmed and Sci-e) were searched between 31 October-3 November 2014. also, abstracts of congresses by three national congresses were searched for studies regarding infective endocarditis. Results: Data for 1270 patients (38.3% female, mean age 46.2, 28% prosthetic valve endocarditis) with a diagnosis of infective endocarditis were obtained from 21 reports (18 published articles and three congress abstracts). Of the 18 articles, four were in peer-reviewed medical journals indexed in national databases and 14 were in international databases. There was an underlying heart disease in 51.9% and history of dental procedure was 6.7%. Fever, heart murmur and fatigue were present in 94%, 71.4% and 69% respectively. most commonly involved site was mitral valve (43.3%), followed by aortic (33.8%) and tricuspid valve (6.4%). Staphylococcus aureus, coagulase-negative staphylococci and enterococci comprised the 22.8%, 9.7% and 7.5% of the cases while 31.1% were culture-negative. Overall mortality was 23.4%. When we compared series related to years 2008 and before and 2009 and after, the mortality rates were (24.1%-224/931) vs (20.1%-32/159), respectively (p = 0,31). Conclusion: Infective endocarditis is still associated with significant mortality. S. aureus seems to be the most common etiologic agent. There was a slight decrease in the recent years in mortality.

show abstract

“…It is wellestablished as an antibiotic since 2003, marketed as Cubicin Ò (Chan Tompkins and Harnicar 2008). Daptomycin has been successfully administered for skin infections, endocarditis, osteomyelitis, soft-tissue infections, even anthrax (Kaya et al 2013;Gould et al 2013;Xing et al 2014). …”

Section: Daptomycinmentioning

confidence: 98%

“…It upsets the membrane potential of Gram-positive bacteria (Kanafani and Corey 2007). When administered to left heart endocarditis patients, it inhibited methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus mutans without any side effects (Kaya et al 2013). At an MIC value of 0.78 lg/ml, it eradicated the anthrax pathogen Bacillus anthracis AP422, by perturbing the latter's membrane potential.…”

Section: Antibacterialmentioning

confidence: 99%

Therapeutic cyclic lipopeptides mining from microbes: latest strides and hurdles

Patel

Ahmed

Eswari

2015

World J Microbiol Biotechnol

View full text Add to dashboard Cite

Infectious diseases impose serious public health burdens and often have devastating consequences. The cyclic lipopeptides elaborated by bacteria Bacillus, Paenibacillus, Pseudomonas, Streptomyces, Serratia, Propionibacterium and fungus Fusarium are very crucial in restraining the pathogens. Composed of a peptide and a fatty acyl moiety these amphiphilic metabolites exhibit broad spectrum antimicrobial effects. Among the plethora of cyclic lipopeptides, only selective few have emerged as robust antibiotics. For their functional vigor, polymyxin, daptomycin, surfactin, iturin, fengysin, paenibacterin and pseudofactin have been integrated in mainstream healthcare. Daptomycin has been a significant part of antimicrobial arsenal since the past decade. As the magnitude of drug resistance rises in unprecedented manner, the urgency of prospecting novel cyclic lipopeptides is being perceived. Intense research has revealed the implication of these bioactive compounds stretching beyond antibacterial and antifungal. Anticancer, immunomodulatory, prosthetic parts disinfection and vaccine adjuvancy are some of the validated prospects. This review discusses the emerging applications, mechanisms governing the biological actions, role of genomics in refining structure and function, semi-synthetic analog discovery, novel strain isolation, setbacks etc. Though its beyond the scope of the current topic, for holistic purpose, the role of lipopeptides in bioremediation and crop biotechnology has been briefly outlined. This updated critique is expected to galvanize innovations and diversify therapeutic recruitment of microbial lipopeptides.

show abstract

Treatment of Gram-positive left-sided infective endocarditis with daptomycin

Cited by 10 publications

References 21 publications

High-Dose Daptomycin Therapy for Left-Sided Infective Endocarditis: a Prospective Study from the International Collaboration on Endocarditis

High-Dose Daptomycin Therapy for Left-Sided Infective Endocarditis: a Prospective Study from the International Collaboration on Endocarditis

Pooled analysis of 1270 infective endocarditis cases in Turkey

Therapeutic cyclic lipopeptides mining from microbes: latest strides and hurdles

Contact Info

Product

Resources

About